Literature DB >> 30022375

Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes.

Xia Wang1,2,3, Peilin Zheng1,2, Gan Huang1,2, Lin Yang1,2, Zhiguang Zhou4,5.   

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors constitute a novel class of anti-diabetic agents confirmed to improve glycemic control and preserve β-cell function in type 2 diabetes. Three major large-scale studies, EXAMINE, SAVOR-TIMI 53, and TECOS, have confirmed the cardiovascular safety profile of DPP-4 inhibitors. Based on these results, DPP-4 inhibitors have gained widespread use in type 2 diabetes treatment. It is currently unknown, however, whether DPP-4 inhibitors have similar therapeutic efficacy against autoimmune diabetes. Several in vitro and in vivo studies have addressed this issue, but the results remain controversial. In this review, we summarize experimental findings and preliminary clinical trial results, and identify potentially effective immune modulation targets of DPP-4 inhibitors for autoimmune diabetes.

Entities:  

Keywords:  DPP-4 inhibitor; Incretin; Latent autoimmune diabetes in adults; Type 1 diabetes

Mesh：

Substances：

Year:  2018        PMID： 30022375     DOI： 10.1007/s10238-018-0519-0

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN： 1591-8890            Impact factor:   3.984


  93 in total

1.  Insulin autoantibody could help to screen latent autoimmune diabetes in adults in phenotypic type 2 diabetes mellitus in Chinese.

Authors:  Gan Huang; Xia Wang; Zhangwei Li; Hui Li; Xia Li; Zhiguang Zhou
Journal:  Acta Diabetol       Date:  2010-05-16       Impact factor: 4.280

2.  Islet cell antibodies (ICA) identify autoimmunity in children with new onset diabetes mellitus negative for other islet cell antibodies.

Authors:  Cecilia Andersson; Martin Kolmodin; Sten-Anders Ivarsson; Annelie Carlsson; Gun Forsander; Bengt Lindblad; Johnny Ludvigsson; Ingrid Kockum; Claude Marcus; Ulf Samuelsson; Eva Ortqvist; Ake Lernmark; Helena Elding Larsson; Carina Törn
Journal:  Pediatr Diabetes       Date:  2013-11-10       Impact factor: 4.866

3.  [From the correspondence on the Auschwitz issue of Przeglad Lekarsi (IX)].

Authors:  J Masłowski
Journal:  Przegl Lek       Date:  1987

Review 4.  Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.

Authors:  Christian Seerup Frandsen; Thomas Fremming Dejgaard; Sten Madsbad
Journal:  Lancet Diabetes Endocrinol       Date:  2016-03-09       Impact factor: 32.069

5.  Protein tyrosine phosphatase-like protein IA2-antibodies plus glutamic acid decarboxylase 65 antibodies (GADA) indicates autoimmunity as frequently as islet cell antibodies assay in children with recently diagnosed diabetes mellitus.

Authors:  H Borg; P Fernlund; G Sundkvist
Journal:  Clin Chem       Date:  1997-12       Impact factor: 8.327

6.  Insulin treatment in patients with type 1 diabetes induces upregulation of regulatory T-cell markers in peripheral blood mononuclear cells stimulated with insulin in vitro.

Authors:  Minna Tiittanen; Johanna T Huupponen; Mikael Knip; Outi Vaarala
Journal:  Diabetes       Date:  2006-12       Impact factor: 9.461

7.  Zinc transporter 8 autoantibody (ZnT8A) could help differentiate latent autoimmune diabetes in adults (LADA) from phenotypic type 2 diabetes mellitus.

Authors:  Gan Huang; Yufei Xiang; Lingling Pan; Xia Li; Shuoming Luo; Zhiguang Zhou
Journal:  Diabetes Metab Res Rev       Date:  2013-07       Impact factor: 4.876

8.  Tetraspanin 7 autoantibodies in type 1 diabetes.

Authors:  Denise Walther; Anne Eugster; Sibille Jergens; Anita Gavrisan; Christina Weinzierl; Tanja Telieps; Christiane Winkler; Anette G Ziegler; Ezio Bonifacio
Journal:  Diabetologia       Date:  2016-05-25       Impact factor: 10.122

9.  Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study.

Authors:  Zhifang Yang; Zhiguang Zhou; Xia Li; Gan Huang; Jian Lin
Journal:  Diabetes Res Clin Pract       Date:  2008-11-12       Impact factor: 5.602

10.  Identification of Tetraspanin-7 as a Target of Autoantibodies in Type 1 Diabetes.

Authors:  Kerry A McLaughlin; Carolyn C Richardson; Aarthi Ravishankar; Cristina Brigatti; Daniela Liberati; Vito Lampasona; Lorenzo Piemonti; Diana Morgan; Richard G Feltbower; Michael R Christie
Journal:  Diabetes       Date:  2016-03-07       Impact factor: 9.461
View more
  6 in total

1.  The Bone-Forming Properties of Periosteum-Derived Cells Differ Between Harvest Sites.

Authors:  Lisanne C Groeneveldt; Tim Herpelinck; Marina Maréchal; Constantinus Politis; Wilfred F J van IJcken; Danny Huylebroeck; Liesbet Geris; Eskeatnaf Mulugeta; Frank P Luyten
Journal:  Front Cell Dev Biol       Date:  2020-11-25

Review 2.  Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales.

Authors:  Amelia D Dahlén; Giovanna Dashi; Ivan Maslov; Misty M Attwood; Jörgen Jonsson; Vladimir Trukhan; Helgi B Schiöth
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

Review 3.  Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases.

Authors:  Xiaopeng Hu; Xisheng Wang; Xingkui Xue
Journal:  Molecules       Date:  2022-07-14       Impact factor: 4.927

4.  Research on ACEI of Low-Molecular-Weight Peptides from Hirudo nipponia Whitman.

Authors:  Zhao Ding; Keli Chen; Yunzhong Chen
Journal:  Molecules       Date:  2022-08-24       Impact factor: 4.927

5.  Assessment of serum dipeptidyl peptidase-IV levels in autoimmune thyroid disease.

Authors:  Yuanyuan Zhang; Ying Fu; Yuxian Yang; Jing Ke; Dong Zhao
Journal:  J Int Med Res       Date:  2022-07       Impact factor: 1.573

6.  Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus.

Authors:  Abid Shaheer; Ashok Kumar; Palat Menon; Mahir Jallo; Shaikh Basha
Journal:  J Clin Med Res       Date:  2021-06-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.